- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Mentari Therapeutics, Inc.(MTRI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MTRI
11/13/2026: MTRI (1-star) is a SELL. SELL for 4 days. Simulated Profits (-23.27%). Updated daily EoD!
Mentari Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for migraine prevention, featuring lead candidates like MT-001 and MT-002. The company's primary strength lies in its innovative approach targeting validated PACAP and CGRP pathways to address patients unresponsive to standard treatments. Its main growth opportunity rests on successful clinical advancement and potential commercialization within the lucrative neurology market. However, the company faces high risks typical of early-stage biotech, including binary clinical trial outcomes and intense competition from pharmaceutical giants. Mentari is best suited for growth-oriented investors comfortable with high volatility and clinical development risk.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to high-growth clinical-stage biotechnology innovation targeting large neurology markets. |
| Momentum investor | Strong fit while signal remains positive | Clinical catalysts and news flow can trigger sharp near-term price movements typical of clinical-stage biotech stocks. |
| Value investor | Weak fit | The company lacks commercial earnings or traditional value-metric support at this stage of clinical development. |
| Dividend investor | Weak fit | As a pre-revenue clinical-stage biotech, Mentari does not pay dividends. |
| Low-risk investor | Weak fit | High clinical development risks and share price volatility make it unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience dramatic price swings based on trial data and market sentiment. |
| Valuation risk | High | Valuation is heavily dependent on future clinical success and pipeline potential rather than current revenue. |
| Competition risk (large pharmaceutical competition) | High | The migraine treatment market features entrenched, well-funded competitors with established commercial footprints. |
| Business quality | Medium | The company possesses promising scientific assets, but lacks the commercial-stage infrastructure of established drug makers. |
| Dividend income | Low / none | No dividends are paid or anticipated in the foreseeable future. |
| Execution risk | High | Success relies entirely on the smooth execution of complex preclinical and clinical development programs. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 17.8K shares | Beta - | 52 Weeks Range 5.75 - 23.30 | Updated Date 11/14/2026 |
52 Weeks Range 5.75 - 23.30 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -69.95% | Avg. Invested days 15 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic R&D and Pipeline Development | Future commercialization rights, potential milestone payments, and product sales stemming from migraine therapies like MT-001 and MT-002. | The company does not make money yet; future returns depend on successfully developing and commercializing drugs. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.05B | Price to Sales(TTM) - |
Enterprise Value 1.05B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 58.30M | Shares Floating - |
Shares Outstanding 58.30M | Shares Floating - | ||
Percent Insiders - | Percent Institutions 1.38 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

